4.3 Article

Pre-operative Carboplatin/Paclitaxel Versus 5-Fluorouracil (5-FU)-based Chemoradiotherapy for Older Adults With Esophageal Cancer

Journal

ANTICANCER RESEARCH
Volume 42, Issue 1, Pages 59-66

Publisher

INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.15457

Keywords

Esophageal cancer; geriatric oncology; trimodality therapy; platinum; 5-fluouracil; carboplatin; paclitaxel

Categories

Ask authors/readers for more resources

This study compared the efficacy and tolerability of two chemotherapy regimens in older patients with advanced esophageal cancer. The results showed that the less toxic CP regimen can achieve similar tumor response and survival rates as the P5F chemotherapy in older patients.
Background/Aim: This study aimed to compare the efficacy and tolerability of pre-operative platinum/5fluorouracil (P5F) and carboplatin/paclitaxel (CP), in combination with radiation therapy in older adults with locally advanced, stage I-III esophageal cancer. Patients and Methods: We retrospectively reviewed 51 patients aged >= 70 years who underwent chemoradiotherapy followed by esophagectomy for stage I-III esophageal cancer between 2008 and 2018. Pathological complete response (pCR) and survival rates were compared across the two chemotherapy (p=0.89), and partial response rates were similar across both chemotherapy groups. Overall survival (OS) and disease-free survival (DFS) were similar across both groups with HR=0.80 (p=0.62) and HR=0.72 (p=0.72) respectively. Conclusion: The lesser toxic CP regimen may be used in older patients with locally advanced esophageal cancer, with tumor response and survival rates similar to P5F chemotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available